Nine Lives: Alcon’s Pataday Brochure Draws Yet Another FDA Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s most recent advertising letter to Alcon about its marketing practices makes the ninth such letter sent to the ophthalmology-focused firm in roughly 10 years; this time, the Office of Prescription Drug Promotion says the Novartis unit has omitted material facts and overstated efficacy and superiority in a brochure for Pataday.